(Q46573306)

23 December 2017

editorial

0 references

review article

1 reference

title

The taxane limbo: how low can we go? (English)

1 reference

23 December 2017

author name string

Clifford Hudis

series ordinal

1

1 reference

23 December 2017

Chau Dang

series ordinal

2

1 reference

23 December 2017

language of work or name

English

0 references

publication date

27 May 2008

1 reference

23 December 2017

Journal of the National Cancer Institute

published in

1 reference

23 December 2017

volume

100

1 reference

23 December 2017

issue

11

1 reference

23 December 2017

page(s)

761-763

1 reference

23 December 2017

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Taxanes in adjuvant breast cancer setting: which standard in Europe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Tau protein is involved in the apoptotic process induced by anti-microtubule agents on neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN155

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN155

1 reference

23 December 2017

PubMed ID

18505966

1 reference

23 December 2017